Novo Nordisk Slashes US Drug Prices by Up to 50% for Semaglutide Products Starting 2027

Novo Nordisk announced a major pricing restructuring for its obesity and diabetes medications in the United States, with list prices dropping significantly beginning January 1, 2027. The company will standardize wholesale acquisition costs (WAC) at $675 for its semaglutide portfolio, representing a dramatic shift in its US pricing strategy that could reshape patient access to these medications.

Breakdown of Price Cuts: Up to 50% Reduction Across Products

The pricing adjustment varies by product. Wegovy (semaglutide injection 2.4 mg and tablets 25 mg) will see a 50% price reduction from current list prices, while Ozempic (semaglutide injection in 0.5 mg, 1 mg, and 2 mg formulations) faces a 35% cut. Rybelsus (semaglutide tablets 7 mg or 14 mg) will also shift to the new $675 pricing structure. These reductions mark one of the most aggressive pricing moves in the GLP-1 medication category, signaling intensifying competition in the weight-loss and diabetes treatment markets.

Expanding Access for Over 135 Million Patients Nationwide

The decision targets a massive patient population: more than 100 million Americans living with obesity and over 35 million with type 2 diabetes. By reducing the sticker price, Novo Nordisk aims to address a critical pain point—out-of-pocket costs that often track the official list price. The company emphasized that these semaglutide medications offer broader clinical applications and stronger efficacy profiles compared to competing GLP-1 treatments, justifying the premium positioning these products have maintained.

Strategic Timing and Direct-to-Patient Pricing Considerations

Notably, the 2027 effective date gives the company time to navigate existing contracts and insurance arrangements. The pricing changes apply exclusively to list prices and WAC; they do not affect direct-to-patient, self-pay programs, meaning patients accessing these medications through cash-pay or discount programs may not see immediate savings. This distinction suggests Novo Nordisk is strategically managing its revenue streams across different patient segments while appearing responsive to access concerns in the broader market conversation.

The move reflects broader industry pressure to demonstrate medication accessibility, particularly as GLP-1 treatments face mounting scrutiny over affordability despite their clinical benefits.